Year-end Sale % OFF 
Abstract
Ertapenem is a parenteral carbapenem that was licensed in the United States in November 2001. It is highly active in vitro against oxacillin-susceptible staphylococci, Streptococcus pneumoniae, β-hemolytic streptococci, Haemophilus spp., Moraxella catarrhalis, Enterobacteriaceae, and anaerobes but has limited activity against enterococci, Pseudomonas aeruginosa, and other nonfermentative gram-negative bacilli. Based on this spectrum of activity, ertapenem is most appropriate for treating community-acquired infections; it should not be used for empiric treatment of infections acquired in an intensive-care unit. Ertapenem is administered either intravenously or intramuscularly and has an elimination half-life of approximately 4 h. The recommended dose is 1 g once a day. No dose adjustment is required for elderly adults or patients with mild to moderate renal insufficiency; however, for patients with a creatinine clearance of ≤30 ml/min, a dose of 500 mg once a day is recommended. In large, adequately powered, clinical trials, ertapenem was shown to be highly effective for treating adults with complicated intra-abdominal infection, complicated skin/skin structure infection, acute pelvic infection, complicated urinary tract infection, or community-acquired pneumonia.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
